RxDoctor Payments Data

Alexander Parker, MD

Urology · Saint Louis, MONPI 1770003162

Payments from drug & device makers

$7,490in general payments, 2019–2025

Across 274 payments — averaging $27.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$794
  • Sumitomo Pharma America, Inc.$753
  • Johnson & Johnson$731
  • Baxter Healthcare$595
  • Boston Scientific$582
  • Dendreon Pharmaceuticals LLC$520
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$6,86392%
  • Education$6088%
  • Entertainment$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,490 in reported general payments places this provider in the 70th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$402,996
Medicare patients
713
Services billed
13,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide40$539,534
ErleadaApalutamide31$453,536
OrgovyxRelugolix116$294,001
MyrbetriqMirabegron168$110,159
GemtesaVibegron28$25,840
Tamsulosin Hcl573$8,235
Finasteride334$3,923
Alfuzosin Hcl ErAlfuzosin Hcl55$1,282
Potassium Citrate ErPotassium Citrate22$1,206
Estradiol19$1,091
Dutasteride33$1,074
Testosterone Cypionate25$740
CefuroximeCefuroxime Axetil72$695
Trospium Chloride17$622
Bicalutamide22$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$794$649,693208 claims
Johnson & JohnsonErleada$731$453,53631 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$753$319,841144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 250 urology providers in Missouri.

Other urology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →